New pill targets Hard-to-Treat KRAS cancers in early human trial

NCT ID NCT06243354

Recruiting now Disease control Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug, HYP-2090PTSA, in people with advanced solid tumors that have a specific genetic change called KRAS mutation. The trial has two parts: first, finding the safest dose, and then testing how well that dose works in certain cancers. About 257 adults with advanced cancer will take part. The goal is to control the disease, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFICACY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFFICACY SAFETY TOLERABILITY

Contacts and locations

Locations

Fujian Provincial Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350000, China
Hunan Provincial Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410000, China
Shandong Provincial Cancer Hospital
NOT_YET_RECRUITING

Jinan, Shandong, 250000, China
Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China
The first Hospital of China Medical University
NOT_YET_RECRUITING

Shenyang, Liaoning, 110000, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.